ALS

Sessions focused on AI, breathing control, aging and traumatic brain injury — research areas of strength at UF.

The McKnight Brain Institute’s signature programs in neurological diseases include brain tumor immunotherapy and a range of neurodegenerative disorders including ALS, Alzheimer’s disease and Parkinson’s disease. The MBI is dedicated to accelerating discoveries in these fields to enhance brain health and develop innovative therapies. 1Florida Alzheimer’s Disease Research Center…

The McKnight Brain Institute’s signature programs in age-related cognitive decline, developmental disorders, sensory dysfunction, pain, and neuropsychiatric diseases including substance use disorders. The MBI is dedicated to accelerating discoveries to enhance brain health and develop innovative therapies. Center for Addiction Research & Education (CARE) CARE facilitates collaborative…

The McKnight Brain Institute’s signature programs in acquired neural injury include neural control of respiration, spinal cord injury, stroke and traumatic brain injury. The MBI is dedicated to accelerating discoveries to enhance brain health and develop innovative therapies. Brain Injury, Rehabilitation, and Neuroresilience Center (BRAIN) BRAIN Center…

At the Southeastern Neurodegenerative Disease Conference, main focus was advancing careers of newest investigators.

Drs. James Wymer and Michael Okun contributed to annual NEJM Group publication.

UF neuroscientists collaborate on international study revealing a potential therapeutic target for ALS, FTD linked to TDP-43.

AMX0035 was tested at UF, Mass General and partnering sites and then approved by the FDA to treat ALS.

Ariel Walker is the latest MBI Rising Star, a video series highlighting up-and-coming neuroscience researchers at UF.

Trial drug combination shows potential to prolong survival of ALS patients by more than six months.